In the animal study, the combine use of afatinib and cetuximab, the EGFR-specific antibody, can dramatic shrinkage of erlotinib-resistant tumors harboring the T790M mutation [46], There are also the clinical trials in the combination of afatinib and cetuximab for EGFR-mutant lung cancers with acquired resistance to gefitinib or erlotinib, both with and without T790M mutations. The gene discussed is EGFR; the disease is lung cancer.